Breakthrough Brain-Computer Interface Chip Restores Sight, Securing European Regulatory Approval

11:11

By: Azzat Manal

Breakthrough Brain-Computer Interface Chip Restores Sight, Securing European Regulatory Approval

Science Corporation, a pioneering neurotechnology firm specializing in brain-computer interface (BCI) development, has secured European regulatory approval to market an innovative medical device designed to restore vision in patients suffering from age-related macular degeneration.

The company announced that its flagship device, known as PRIMA, has also received a breakthrough designation from the US Food and Drug Administration (FDA). This critical milestone paves the way for an expedited review process, potentially accelerating access for patients battling rare forms of blindness.

Implantable Microchip and Smart Glasses

Millions of individuals worldwide are affected by age-related macular degeneration, a degenerative condition that damages light-sensitive cells in the retina, making everyday tasks like reading and recognizing faces exceptionally difficult.

The PRIMA system relies on a minimally invasive surgical procedure lasting roughly one hour, during which a microchip is implanted beneath the retina. Post-surgery, patients wear specialized glasses equipped with an external camera that captures their surroundings and projects visual data onto the chip, which in turn stimulates the retina to provide functional sight.

Max Hodak, founder and CEO of Science Corporation and a former co-founder of Neuralink, noted the profound impact the technology has already had on clinical trial participants. Patients have reported reading full-length novels, solving crossword puzzles, and regaining functional independence.

Strategic Acquisition and Future Growth

Science Corporation acquired the foundational technology from the French firm Pixium Vision in 2024, refining the product to meet stringent regulatory standards. The company plans to roll out the PRIMA system commercially in Germany, where initial clinical trials took place, with the first commercial procedures anticipated as early as September.

Looking ahead, the firm aims to develop advanced iterations of the microchip and streamline the wearable hardware, while leveraging commercial revenues to fund broader research into next-generation neural interfaces.